TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News

NYSE:TAK - US8740602052 - ADR

15.16 USD

+0.17 (+1.13%)

Last: 9/2/2025, 7:00:00 PM

15.16 USD

0 (0%)

After Hours: 9/2/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TAK Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Yahoo Finance

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

11 days ago - By: Benzinga - Mentions: IONS

What's Going On With Takeda Stock On Friday?

12 days ago - By: Benzinga - Mentions: BCRX IONS KALV

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

3 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

4 months ago - By: Zacks Investment Research - Mentions: MFG LTM FIVN

Top 4 GARP Stocks With Attractive PEG Ratios to Watch

a month ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

a month ago - By: Investor's Business Daily - Mentions: RY RY.CA ALKS CNTA ...

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.

a month ago - By: Takeda Pharmaceutical Company Limited

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

4 months ago - By: Zacks Investment Research - Mentions: SKM PHIN

Best Value Stocks to Buy for April 30th

4 months ago - By: Zacks Investment Research - Mentions: SNE DB CIVB SPOT ...

New Strong Buy Stocks for April 30th

5 months ago - By: Zacks Investment Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

2 months ago - By: Yahoo Finance

Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

5 months ago - By: Zacks Investment Research

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

2 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces New Assignments of Directors

3 months ago - By: Takeda Pharmaceutical Company Limited

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

3 months ago - By: Takeda Pharmaceutical Company Limited - Mentions: PTGX

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

3 months ago - By: Takeda Pharmaceutical Company Limited

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

4 months ago - By: Yahoo Finance - Mentions: MSFT VRT NVDA META ...

Build 2025 Highlights Microsoft (MSFT)’s Push Toward a Collaborative AI Future

4 months ago - By: Yahoo Finance - Mentions: NVDA VRT CMI MSFT ...

Vertiv Enhances AI Infrastructure with NVIDIA (NVDA) 800V DC

4 months ago - By: Takeda Pharmaceutical Company Limited

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

4 months ago - By: Yahoo Finance - Mentions: AAPL MSFT C

US and China to slash tariffs for 90 days as Trump and Xi likely to talk 'maybe at the end of the week'

4 months ago - By: Investor's Business Daily - Mentions: GILD PFE NVS ABBV ...

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform

4 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

4 months ago - By: Zacks Investment Research

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

4 months ago - By: Zacks Investment Research

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

4 months ago - By: Takeda Pharmaceutical Company Limited

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

4 months ago - By: Zacks Investment Research - Mentions: GRFS ADMA

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?

4 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

4 months ago - By: Yahoo Finance - Mentions: ABEV PAA EQNR CCU ...

Why Ambev SA (ABEV) is Surging in 2025

4 months ago - By: Takeda Pharmaceutical Company Limited

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education